Journal of Transportation Engineering, Part B: Pavements

Alignment Healthcare Introduces Diverse 2024 Medicare Advantage Portfolio to Address Clinical and Social Needs of Seniors Today, from Part B Rebates to Special Benefits for Vulnerable Populations

Retrieved on: 
Monday, October 2, 2023
Well, Podiatry, Acupuncture, Food, Medicare (United States), Diabetes, Pest control, Disability, HMO, Ageing, Foot, Medicare Part D, Dentures, Part, Social Security, Chiropractic, ACCESS, Alignment, Social, Journal of Transportation Engineering, Part B: Pavements, Hearing, OTC, Case management, LIS, Health, Transport, Health insurance, Nursing, Online shopping, Medicaid, Medicare

“More seniors are choosing Alignment because our clinical and member teams take great care to listen and respond to their changing needs,” said Dawn Maroney, president, markets of Alignment Healthcare, and CEO of Alignment Health Plan.

Key Points: 
  • “More seniors are choosing Alignment because our clinical and member teams take great care to listen and respond to their changing needs,” said Dawn Maroney, president, markets of Alignment Healthcare, and CEO of Alignment Health Plan.
  • “We are committed to always putting our seniors first and serving them.
  • With 12.9 million people jointly enrolled in Medicare and Medicaid, Alignment continues to invest in products that support the unique needs of low-income seniors with disabilities or chronic conditions.
  • For members with qualifying conditions, Alignment is extending coverage of pest control and pet boarding, sitting and walking services to all plans in 2024.

Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

Retrieved on: 
Monday, July 17, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ALN, Central nervous system, Cerebrospinal fluid, Cerebral amyloid angiopathy, CAA, Therapy, Regeneron Pharmaceuticals, AFL, Eye, Clinical trial, Brain, Biomarker, CNS, Medication, Gene silencing, AAIC, Journal of Transportation Engineering, Part B: Pavements, Medical director, MD, Patient, Proteolysis, Hematology, Alnylam Pharmaceuticals, RNA interference, CSF, FRCPC, APP, Medicare Part D, AD, Conference, Urinalysis, Safety, ALNY, Medical device, Pharmaceutical industry, Part, Capella

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today updated positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today updated positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).
  • The results were presented at the 2023 Alzheimer’s Association International Conference (AAIC) being held July 16-20, 2023 in Amsterdam, The Netherlands.
  • ALN-APP is being developed in collaboration with Regeneron Pharmaceuticals, Inc.
    Twenty patients with early-onset Alzheimer’s disease have been enrolled in three single-dose cohorts in Part A of the ongoing Phase 1 study.
  • In this study to date, single doses of ALN-APP, which are administered by intrathecal injection, have been well tolerated.

Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

Retrieved on: 
Monday, October 24, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Serum, Metabolic acidosis, Maintenance, Patient, Hypertension, Anemia, Headache, Șaeș, Henry IV, Part I and Part II (The Hollow Crown), CKD, Journal of Transportation Engineering, Part B: Pavements, COVID-19, Chemistry (relationship), Incidence, Hyperkalemia, Pharmaceutical industry, Part

Of the 1,480 patients randomized into Part B, the average increase from baseline in serum bicarbonate was 5.9 mEq/L, increasing from 17.5 mEq/L to 23.4 mEq/L.

Key Points: 
  • Of the 1,480 patients randomized into Part B, the average increase from baseline in serum bicarbonate was 5.9 mEq/L, increasing from 17.5 mEq/L to 23.4 mEq/L.
  • In light of the disappointing results from the trial, and our cash runway, we are evaluating next steps.
  • The incidence of all-cause death (14.2% vs. 14.0%) and cardiovascular death (5.7% vs. 6.0%) was balanced between patients randomized to veverimer and placebo.
  • Tricida will host a conference call and webcast that will include a slide presentation at 8:00 am Eastern Time to discuss the results of the VALOR-CKD clinical trial:

Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Monday, August 8, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Research and development, U.S. Securities and Exchange Commission, Everolimus, Survival, ASCO, CEO, SEC, Patent, Cancer, Clinical trial, Investment, Security (finance), RAMP, Patient, BRAF, KRAS, Journal of Transportation Engineering, Part B: Pavements, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, General Administration of Sport of China, Part, Sale, Breakthrough therapy, Government, FAK, Pancreatic cancer, ARAF, Table, RAF, Verastem Oncology, RAS, American Society of Clinical Oncology, Income, NSCLC, Oncology, Mission statement, Amgen, Mirati, Â, CRAF, Achievement, Society, Review, Company, GAAP, Research, MEK, Progression-free survival, Pharmaceutical industry, Bank, Medical imaging

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended June 30, 2022, and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended June 30, 2022, and highlighted recent progress.
  • The Company plans to complete enrollment of all four cohorts of the trial in the second half of this year.
  • The Company expects to report topline results from Part A, initiate Part B and discuss the data with regulatory authorities during the second half of 2022.
  • Verastem Oncology ended the second quarter 2022 with cash, cash equivalents and investments of $94.3 million.

Performant Introduces Performant Healthcare Solutions as New Trade Name

Retrieved on: 
Wednesday, June 22, 2022
Technology, Finance, Hospitals, Professional Services, Software, Managed Care, Health, General Health, Data Management, Journal of Transportation Engineering, Part B: Pavements, Center for Medicare and Medicaid Innovation, Government, Medicaid, Company, Health, Pay for performance (healthcare), Medicare Part D, Medicare, RAC, DNA, Program, Nasdaq, Center, Medicare (United States), Health insurance

Performant Financial Corporation (Nasdaq: PFMT) (the Company, Performant), a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, today announced a new dba name, Performant Healthcare Solutions, which the Company will begin using immediately.

Key Points: 
  • Performant Financial Corporation (Nasdaq: PFMT) (the Company, Performant), a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, today announced a new dba name, Performant Healthcare Solutions, which the Company will begin using immediately.
  • To learn more about Performant Healthcare Solutions please visit our website, www.performanthealth.com .
  • Performant Healthcare Solutions is a leading provider of technology-enabled audit, recovery, and analytics services in the United States with a focus in the healthcare payment integrity industry.
  • Performant works with healthcare payers through claims auditing and eligibility-based (also known as coordination-of-benefits) services to identify improper payments.

FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

Retrieved on: 
Friday, May 20, 2022
Journal of Transportation Engineering, Part B: Pavements, Office of Inspector General, U.S. Department of Health and Human Services, Hypersensitivity, Center for Drug Evaluation and Research, Disease, Ageing, Public health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Research, Keratitis, Arthralgia, Asthma, Sinusitis, Adolescence, Cosmetics, Parasitism, Patient, Dysphagia, Multimedia, Vaccine, China Biologic Products, Esophagus, Human services, Clinical trial, Adult, FDA, Polyp (medicine), Regeneron Pharmaceuticals, Eosinophilic esophagitis, Center, Smokeless tobacco, Animal, Dietary supplement, Safety, DSQ, Division, Allergy, Eosinophil, Maintenance, Conjunctivitis, Respiratory tract, Atopic dermatitis, Pharmaceutical industry, Part, EOE, Gastroenterology, Dupilumab

Today's action marks the first FDA approval of a treatment for EoE.

Key Points: 
  • Today's action marks the first FDA approval of a treatment for EoE.
  • "Today's approval will fulfill an important unmet need for the increasing number of patients with eosinophilic esophagitis."
  • EoE is a chronic inflammatory disorder in which eosinophils, a type of white blood cell, are found in the tissue of the esophagus.
  • In adults and adolescent patients with EoE, common symptoms include difficulty swallowing, difficulty eating, and food getting stuck in the esophagus.

4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference

Retrieved on: 
Tuesday, May 17, 2022
Biotechnology, Pharmaceutical, Medical Supplies, General Health, Health, FDA, Medical Devices, Other Health, MSD, Pharma, Disease, U.S. Securities and Exchange Commission, International Conference on Emerging Infectious Diseases, AES, China Biologic Products, FEV1, CNS, Piper LBP, AIM, Conference, SEC, Cancer, Journal of Transportation Engineering, Part B: Pavements, Spirometry, Adult, Phase, Agonist, American Thoracic Society, SABA, Pembrolizumab, ICS, ATS, The Rheumatoid Arthritis Quality of Life Questionnaire, Pancreatic cancer, FVC, ACQ, Company, DDDD, Bacteria, Vaccine, Patient, Merck, FDA, LABA, Tolerability, Therapy, CA, IBS, Risk, Irritable bowel syndrome, Poster, Merck & Co., NASDAQ, PEF, Drug Quality and Security Act, Forward-looking statement, Safety, Securities Exchange Act of 1934, Pharmaceutical industry, Mineral wool, Asthma, Part

The poster is being presented at the 2022 American Thoracic Society (ATS) International Conference, May 13-18, 2022 in San Francisco, CA, US.

Key Points: 
  • The poster is being presented at the 2022 American Thoracic Society (ATS) International Conference, May 13-18, 2022 in San Francisco, CA, US.
  • 4D pharma will further bolster these results as we advance the Phase I/II trial into Part B, said Dr. Alex Stevenson, Chief Scientific Officer of 4D pharma.
  • The effects of MRx-4DP0004 improving ACQ scores and reducing patients reliance on SABA rescue medication are very encouraging.
  • Moving forward into the Part B phase of this trial, 4D pharma aims to evaluate MRx-4DP0004 in asthma patients with more symptomatic disease, expected to provide a greater opportunity to demonstrate improvements.

Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients

Retrieved on: 
Wednesday, March 30, 2022
Population, Christie, NASDAQ, Immunotherapy, The Christie NHS Foundation Trust, ORR, CMO, Survival, Patient, Cancer, HIV disease progression rates, NSCLC, OS, Autoimmune disease, ASX, Kinetics, TPS, Â, GLOBE, Journal of Transportation Engineering, Part B: Pavements, PD-L1, University, Disease, Pembrolizumab, University of Manchester, Health insurance, Pharmaceutical industry, Medical imaging

The new data reflects the first interim results combining Stages 1 (23 patients) and 2 (13 patients) in 2nd line NSCLC.

Key Points: 
  • The new data reflects the first interim results combining Stages 1 (23 patients) and 2 (13 patients) in 2nd line NSCLC.
  • The early signs are supportive that efti may boost the patients immune system to enable pembrolizumab to work more effectively in these patients with advanced lung cancer, while being safe and well tolerated.
  • These patients are a challenging population to treat, having progressed after previous lines of immunotherapy or chemo-immunotherapy and have limited options available for further treatment.
  • So, it is pleasing to see the potential that efti in combination with pembrolizumab has to provide meaningful benefit in this patient group.

Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis

Retrieved on: 
Monday, February 28, 2022
Compliance, Psoriasis Area and Severity Index, Oral medicine, Failure, COVID-19, KOL, Scalp, Private Securities Litigation Reform Act, Research, Incidence, PGA, Depression, Risk, Growth, Inflammation, Atopic dermatitis, Safety, Disease, Skin, Fatigue, Capsule, Doctor of Philosophy, Population, Immune system, FAAD, Psoriasis, Journal of Transportation Engineering, Part B: Pavements, Confidentiality, Patient, Arthritis, GLOBE, Production part approval process, Ownership, Investor, Perelman School of Medicine at the University of Pennsylvania, Association, University, Associate, Adult, Metabolic syndrome, Preclinical development, FDA, T helper cell, Marketing, MD, Dermatology Life Quality Index, SEC, Pharmaceutical industry, Dermatology, Part

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data from the post-treatment follow-up (Part B) of its Phase 2 trial of EDP1815 in mild and moderate psoriasis which included durable and deeper clinical responses. EDP1815 is an investigational oral biologic currently in development for the treatment of a broad range of inflammatory diseases, including clinical programs in psoriasis, atopic dermatitis, and COVID-19.

Key Points: 
  • EDP1815 is an investigational oral biologic currently in development for the treatment of a broad range of inflammatory diseases, including clinical programs in psoriasis, atopic dermatitis, and COVID-19.
  • With the clinical responses and safety and tolerability results comparable to placebo observed in trials involving over 450 patients to-date, we look forward to advancing EDP1815 towards Phase 3 clinical trials.
  • These durable results were achieved without any new psoriasis medication being used during this time.
  • These data, combined with the durability data, suggest that longer dosing could lead to further deepening of the responses in some patients.